Anteo Diagnostics : Strengthening IP in Medical Devices

12 January 2017 Anteo Diagnostics Strengthening its Intellectual Property Position in Medical Device Arena

• Two Controlled Competitive Exchange patent applications progress to PCT Phase.
• Heterofunctional Binding Systems patent application progresses to National Phase
• Conductive Fibres provisional patent application filed

Anteo Diagnostics Limited (ASX: ADO) is pleased to announce further expansion and strengthening of its IP position in the Medical Device arena. Together with Anteo's background IP in Diagnostics, other Life Science related applications, and Energy, there is now significant IP expansion and coverage of multiple applications within Medical Devices.

Ms Tamara Mills, COO of Anteo Technologies said: "With a background in medical device development and commercialisation, I have taken a particular interest in how Anteo's nanochemistry can be applied to Medical Devices. Anteo's core technology can be used to create lubricious coatings particularly for cardiovascular catheters, guidewires, and urinary catheters, and it can also be used to form more "active" or "interactive" coatings to create anti-thrombogenic or anti-microbial properties. Recent development work in the application of Anteo's Technology in the Medical Device arena discovered a number of new application areas, leading Anteo to establishing a stronger intellectual property position in this exciting field. We are excited by the recent progress we have seen in moving our patent applications through the examination process and in the filing of new applications."

In late November 2016, a patent application describing controlled competitive exchange progressed to the PCT phase. This patent application exemplifies methods of controlled release of active molecular entities and also, amongst others, methods to control reaction kinetics to improve uniformity of the Anteo nanotechnology coating.

Additionally, in December 2016, Anteo received notice of progress in the examination of two additional patent applications. The first patent application describing the development and use of anti-thrombogenic coatings for medical devices progressed to PCT stage.

The second patent application describing the application of a different family of Anteo nanochemistry based coatings, titled "Heterofunctional binding systems", also progressed to National Phase. This patent application describes the use of the Anteo technology for coating hydrophobic, non-lubricous materials and is background IP for all of the Anteo Medical Device applications.

The Anteo intellectual property position in the Medical Devices segment has been further strengthened by the filing of a provisional patent application, in Oct 2016, to cover novel applications of Anteo technology relating to the development of coatings on flexible electrodes useful in sensors and active implantable devices. The Anteo concepts provide significant advantages in the development of more effective neural interfaces for the improvement of hearing, vision or similar devices

"One of the most exciting new development areas being explored, 'flexible electrodes', bridges Anteo's intellectual property and expertise in the Energy space to the medical device space. We are actively seeking development partners in the application of this breakthrough technology in neural prosthetic devices, medical devices that can substitute a motor, sensory or cognitive modality that might have been damaged as a result of an injury or a disease, such as cochlear implants or retina implants." Ms Mills said.

ABOUT ANTEO GROUP - Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for high- value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

Through its wholly owned subsidiary, DIAsource Immunoassays SA, Anteo Group manufactures and distributes a complete catalogue of ELISA and RIA products for clinical diagnostics via established distribution channels in 75 counties across the world, including antibodies and laboratory automation instrumentation.

For more information, please visit www.anteodx.com